Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant (NCT06563895)
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
🩺 Plain-English Summary (8th-Grade Level)
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age. Amyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN. Acoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs. This study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.
Who can join: Review the eligibility criteria below.
Location: University of California, San Diego (UCSD) - Medical Center — La Jolla, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (104 Sites)
Showing the first 25 of 104 sites.
- University of California, San Diego (UCSD) - Medical Center — La Jolla, California
- University of California, Los Angeles (UCLA) - David Geffen School of Medicine — Los Angeles, California
- University of California, San Francisco (UCSF) — San Francisco, California
- Stanford University — Stanford, California
- University of Colorado Anschutz — Aurora, Colorado
- Yale University School of Medicine - Section of Cardiology — New Haven, Connecticut
- MedStar Washington Hospital Center - MedStar Heart and Vascular Institute — Washington D.C., District of Columbia
- Mayo Clinic - Jacksonville — Jacksonville, Florida
- University of Miami — Miami, Florida
- Cleveland Clinic Florida — Weston, Florida
- Emory University School of Medicine — Atlanta, Georgia
- John H. Stroger, Jr. Hospital of Cook County — Chicago, Illinois
- University of Chicago - Medical Center — Chicago, Illinois
- University of Maryland Medical Center — Baltimore, Maryland
- Johns Hopkins University — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Brigham and Women's Hospital — Boston, Massachusetts
- Boston University (BU) School of Medicine — Boston, Massachusetts
- Henry Ford Health System — Detroit, Michigan
- Mayo Clinic - Rochester — Rochester, Minnesota
- St. Luke's Hospital of Kansas City — Kansas City, Missouri
- Washington University in St. Louis — St Louis, Missouri
- Rutgers-Robert Wood Johnson Medical School — New Brunswick, New Jersey
- New York University (NYU) School of Medicine - Langone Medical Center — New York, New York
- Mount Sinai Hospital — New York, New York
📞 Contact the Study Coordinator
Phone: (844) 550-2246
Email: medinfo@eidostx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Amyloidosis
- A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis — Duarte, California
- A Study Of MCG In Cardiac Amyloidosis — Rochester, Minnesota
- Dietary Reporting In The Amyloidoses — Detroit, Michigan
- Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis — Portland, Oregon
- A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography — Rochester, Minnesota
Explore by condition: All Amyloidosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.